Lamivudine resistance in children with chronic hepatitis B

Table 1 Outcomes of different therapeutic regimens in children with chronic hepatitis B

Ref.	Therapeutic regimen	Duration of treatment	HBeAg seroconversion rate (%)	Relapse rate (%)	Breakthrough rate (%)
Jonas et al[9]	LAM	52 wk	26	18	19
Hagmann et al[10]	LAM	126 mo	50	25	19
Sokal et al[15]	LAM	24 mo	25	11	49
		36 mo	35	0	64
Hartman et al[16]	LAM	126 mo	18	0	65
Hong et al[5]	LAM	12 mo	60.5	NA	25.9
Lee et al[17]	LAM	12 mo	60	0	27
Ni et al[18]	LAM	12 mo	38	0	34
Akman et al[19]	LAM	32.3 ± 8.3 mo	20.8	NA	58.4
Choe et al[3]	LAM	126 mo	65	4	103
					234
Liberek et al[20]	LAM	12 mo	27.1	NA	3.38
Koh et al[21]	LAM	126 mo	42	3.3	10
Kansu et al[8]	LAM + IFN	6 m IFN	60.21	6.81	17.91
		24 mo LAM	39.42	02	24.62
Ozgenç et al[29]	LAM + IFN	6 mo IFN	15.63	6.83	13.33
		12-36 mo	5.64		69.44
		LAM	05		82.45
Dikici et al[32]	LAM + IFN	6 mo IFN	37	3.7	3.3
		12 mo LAM
Kuloğlu et al[33]	LAM + IFN	6 mo IFN	34.2	NA	65.8
		126 mo LAM
Saltik-Temizel et al[34]	LAM + IFN	6 mo IFN	60	NA	NA
		12 mo LAM

¹Simultaneous therapy;

²Sequential therapies;

³First year;

⁴Second year;

⁵Third year;

⁶Until HBeAg seroconversion or evidence of resistance. NA: Information was not given in the study; IFN: Interferon; LAM: Lamivudine; HBeAg: Hepatitis B e antigen.